Koichiro Watanabe, MD, PhD

Original Research

Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D2 Receptor Occupancy in Stable Patients With Schizophrenia: Findings From an Open-Label, Randomized, Controlled Study

July 22, 2014

Hiroyoshi Takeuchi, Takefumi Suzuki, Robert R. Bies, et al

Article

A Cross-Sectional Study of Plasma Risperidone Levels With Risperidone Long-Acting Injectable: Implications for Dopamine D2 Receptor Occupancy During Maintenance Treatment in Schizophrenia

August 15, 2012

Saeko Ikai, Gary Remington, Takefumi Suzuki, et al

Article

How Successful Are Physicians in Eliciting the Truth From Their Patients? A Large-Scale Internet Survey From Patients' Perspectives

March 15, 2012

Norifusa Sawada, Hiroyuki Uchida, Koichiro Watanabe, et al

Letter to the Editor

Risks of Intermittent Antipsychotic Treatment in Schizophrenia

January 15, 2011

Takefumi Suzuki, Kensuke Nomura, Koichiro Watanabe

Letter to the Editor

Is There a Real Difference in Severity of Tardive Dyskinesia Between Risperidone and Olanzapine?

November 15, 2010

Takefumi Suzuki, Hiroyoshi Takeuchi, Koichiro Watanabe

Letter to the Editor

Selective Serotonin Reuptake Inhibitor-Induced Spermatorrhea in 2 Patients

August 15, 2009

Shinichiro Nakajima, Hiroyuki Uchida, Takefumi Suzuki, et al

Original Research

Antipsychotic-Induced Hyperprolactinemia Inhibits the Hypothalamo-Pituitary-Gonadal Axis and Reduces Bone Mineral Density in Male Patients With Schizophrenia

March 14, 2008

Taishiro Kishimoto, Koichiro Watanabe, Naoki Shimada, et al

Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D2 Receptor Occupancy in Stable Patients With Schizophrenia: Findings From an Open-Label, Randomized, Controlled Study

A Cross-Sectional Study of Plasma Risperidone Levels With Risperidone Long-Acting Injectable: Implications for Dopamine D2 Receptor Occupancy During Maintenance Treatment in Schizophrenia

How Successful Are Physicians in Eliciting the Truth From Their Patients? A Large-Scale Internet Survey From Patients' Perspectives

Risks of Intermittent Antipsychotic Treatment in Schizophrenia

Is There a Real Difference in Severity of Tardive Dyskinesia Between Risperidone and Olanzapine?

Selective Serotonin Reuptake Inhibitor-Induced Spermatorrhea in 2 Patients

Antipsychotic-Induced Hyperprolactinemia Inhibits the Hypothalamo-Pituitary-Gonadal Axis and Reduces Bone Mineral Density in Male Patients With Schizophrenia

ELSEWHERE:

FOLLOW US:

Koichiro Watanabe, MD, PhD

Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D2 Receptor Occupancy in Stable Patients With Schizophrenia: Findings From an Open-Label, Randomized, Controlled Study

A Cross-Sectional Study of Plasma Risperidone Levels With Risperidone Long-Acting Injectable: Implications for Dopamine D2 Receptor Occupancy During Maintenance Treatment in Schizophrenia

How Successful Are Physicians in Eliciting the Truth From Their Patients? A Large-Scale Internet Survey From Patients' Perspectives

Risks of Intermittent Antipsychotic Treatment in Schizophrenia

Is There a Real Difference in Severity of Tardive Dyskinesia Between Risperidone and Olanzapine?

Selective Serotonin Reuptake Inhibitor-Induced Spermatorrhea in 2 Patients

Antipsychotic-Induced Hyperprolactinemia Inhibits the Hypothalamo-Pituitary-Gonadal Axis and Reduces Bone Mineral Density in Male Patients With Schizophrenia

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles